Mirdametinib in Patients With Advanced NF1-mutant Melanoma
A phase 2 trial of Mirdametinib in Advanced melanoma, run by Kevin Kim, MD, now recruiting.
Overview
Mirdametinib in Patients With Advanced NF1-mutant Melanoma is a phase 2 interventional study registered as NCT07237100 by Kevin Kim, MD, with 10 participants planned, started 2025-10-13 and due to reach its primary completion in 2027-10-13. Interventions recorded: Mirdametinib. Conditions recorded: Advanced Unresectable Melanoma, Metastatic Melanoma.
Linked to the drug Mirdametinib because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTesting the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Shares Mirdametinib and the tag pipeline.
- TrialMirdametinib in Histiocytic Disorders
Shares Mirdametinib and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialAMT-253 in Patients With Advanced Solid Tumours
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialA Study of ST-1898 for Unresectable or Metastatic Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.